HUP0200663A2 - Novel method for producing doxazosin mesylate in a crystalline modification designated as form a - Google Patents

Novel method for producing doxazosin mesylate in a crystalline modification designated as form a Download PDF

Info

Publication number
HUP0200663A2
HUP0200663A2 HU0200663A HUP0200663A HUP0200663A2 HU P0200663 A2 HUP0200663 A2 HU P0200663A2 HU 0200663 A HU0200663 A HU 0200663A HU P0200663 A HUP0200663 A HU P0200663A HU P0200663 A2 HUP0200663 A2 HU P0200663A2
Authority
HU
Hungary
Prior art keywords
doxazosin
doxazosin mesylate
methanol
mesylate
methanesulfonic acid
Prior art date
Application number
HU0200663A
Other languages
English (en)
Hungarian (hu)
Inventor
Peter Klein
Thyes Marco Dr
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of HUP0200663A2 publication Critical patent/HUP0200663A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HU0200663A 1999-03-18 2000-03-06 Novel method for producing doxazosin mesylate in a crystalline modification designated as form a HUP0200663A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19912063A DE19912063A1 (de) 1999-03-18 1999-03-18 Neues Verfahren zur Herstellung von Doxazosin-Mesylat in einer als Form A bezeichneten Kristallmodifikation

Publications (1)

Publication Number Publication Date
HUP0200663A2 true HUP0200663A2 (en) 2002-08-28

Family

ID=7901411

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200663A HUP0200663A2 (en) 1999-03-18 2000-03-06 Novel method for producing doxazosin mesylate in a crystalline modification designated as form a

Country Status (13)

Country Link
EP (1) EP1165548A1 (de)
JP (1) JP2002540109A (de)
KR (1) KR20010113753A (de)
CN (1) CN1352643A (de)
AU (1) AU3960800A (de)
CA (1) CA2367903A1 (de)
CZ (1) CZ20013347A3 (de)
DE (1) DE19912063A1 (de)
HU (1) HUP0200663A2 (de)
IL (1) IL144944A0 (de)
PL (1) PL350088A1 (de)
TR (1) TR200102730T2 (de)
WO (1) WO2000056731A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19912573A1 (de) * 1999-03-19 2000-09-21 Knoll Ag Arzneimittel, enthaltend Doxazosin-Mesylat der Kristallmodifikaton D
RU2186779C1 (ru) * 2001-01-31 2002-08-10 Федеральное государственное унитарное предприятие Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" Способ получения метансульфоната доксазозина
NZ585558A (en) * 2007-12-24 2011-08-26 Cipla Ltd Crystalline polymorph of doxazosin mesylate (form iv) and process for preparation thereof
CN109988158A (zh) * 2018-01-03 2019-07-09 合肥立方制药股份有限公司 X晶型、含有x晶型的多沙唑嗪甲磺酸盐及其制备方法和用途
CN111303130B (zh) * 2018-12-11 2021-09-14 合肥立方制药股份有限公司 一种多沙唑嗪甲磺酸盐晶型、其制备方法及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1287588B1 (it) * 1996-12-13 1998-08-06 Alfa Chem Ital Forma cristallina del doxazosin mesilato e processo per la sua produzione
DE59611417D1 (de) * 1996-12-20 2007-03-29 Heumann Pharma Gmbh & Co Neue polymorphe Form von Doxazosinmesylat (Form III)
DE19800214A1 (de) * 1998-01-06 1999-07-15 Knoll Ag Verfahren zur Herstellung von Doxazosin-Mcsylat in einer als Form A bezeichneten Kristallmodifikation und ein Zwischenprodukt dafür

Also Published As

Publication number Publication date
TR200102730T2 (tr) 2002-06-21
PL350088A1 (en) 2002-11-04
CZ20013347A3 (cs) 2002-01-16
CA2367903A1 (en) 2000-09-28
JP2002540109A (ja) 2002-11-26
CN1352643A (zh) 2002-06-05
DE19912063A1 (de) 2000-09-21
KR20010113753A (ko) 2001-12-28
IL144944A0 (en) 2002-06-30
EP1165548A1 (de) 2002-01-02
WO2000056731A1 (de) 2000-09-28
AU3960800A (en) 2000-10-09

Similar Documents

Publication Publication Date Title
US7300938B2 (en) Polymorphs of imatinib mesylate
ES2565078T3 (es) Forma polimorfa novedosa de mesilato de imatinib y un proceso para su preparación
US20080085903A1 (en) Novel crystalline forms of aripiprazole
EA022813B1 (ru) СПОСОБ ОЧИСТКИ МЕТИЛ{4,6-ДИАМИНО-2-[1-(2-ФТОРБЕНЗИЛ)-1Н-ПИРАЗОЛО[3,4-b]ПИРИДИН-3-ИЛ]ПИРИМИДИН-5-ИЛ}МЕТИЛКАРБАМАТА И ЕГО ПРОИЗВОДНОЕ В ВИДЕ СУЛЬФИНИЛДИМЕТАНА
US20060223816A1 (en) Imatinib mesylate alpha form and production process therefor
AU661483B2 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
SK2982003A3 (en) Preparation of risperidone
WO2003026586A2 (en) Pioglitazone hydrochloride
EP0304941B1 (de) Pharmazeutisch verwendbare polymorphe Modifikation von Buspiron
EP4509508A1 (de) Freie plx5622-kristallform und herstellungsverfahren dafür
JP2755918B2 (ja) テラゾシンモノヒドロクロリド及びその製造法並びに該化合物を製造するための中間体
JP5758010B2 (ja) 酒石酸によるトリアジン誘導体エナンチオマーの分離
HUP0200663A2 (en) Novel method for producing doxazosin mesylate in a crystalline modification designated as form a
JP2702519B2 (ja) 多形結晶形態の転換法
US20090012296A1 (en) Processes for the preparation of crystalline form beta of imatinib mesylate
JP5562337B2 (ja) ドネペジルの多形結晶及びその製造方法
WO2019028144A1 (en) SALTS AND FORMS IN THE SOLID STATE OF PLINABULIN
RU2228931C2 (ru) Кристаллические формы 3-(2,4-дихлорбензил)-2-метил-n-(пентилсульфонил)-3h- бензимидазол-5-карбоксамида
US6500830B1 (en) Conversion of modification D to modification A of doxazosin mesylate
JP4657393B2 (ja) ドキサゾシン・メシレートの新規な形態ｉｉｉ
JP2006321798A (ja) 医薬組成物のために好適な高純度のテルミサルタン型ａを製造するための改良された方法
JP4655930B2 (ja) キノリンカルボン酸誘導体溶媒和物の結晶
HUP0203501A2 (hu) Eljárás epinastin-hidroklorid előállítására magas olvadáspontú kristálymódosulatban
WO2017015784A1 (zh) 奥比特嗪-富马酸盐、水合物、晶型及其制备方法
JP2009173569A (ja) ビス｛２−〔２−（４−ジベンゾ〔ｂ，ｆ〕〔１，４〕チアゼピン−１１−イル−１−ピペラジニル）エトキシ〕エタノール｝モノフマレートの製造方法